Fri, May 14, 2021
Thu, May 13, 2021
Wed, May 12, 2021
Tue, May 11, 2021
Mon, May 10, 2021
Fri, May 7, 2021
Thu, May 6, 2021

Raghuram Selvaraju Maintained (BTAI) at Strong Buy with Decreased Target to $170 on, May 11th, 2021


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. th-decreased-target-to-170-on-may-11th-2021.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Raghuram Selvaraju of HC Wainwright & Co., Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Decreased Target from $175 to $170 on, May 11th, 2021.

Raghuram has made no other calls on BTAI in the last 4 months.



There are 4 other peers that have a rating on BTAI. Out of the 4 peers that are also analyzing BTAI, 0 agree with Raghuram's Rating of Hold.



These are the ratings of the 4 analyists that currently disagree with Raghuram


  • Anita Dushyanth of "Berenberg" Initiated at Strong Buy and Held Target at $75 on, Friday, April 9th, 2021
  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Decreased Target to $127 on, Thursday, April 1st, 2021
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $95 on, Thursday, April 1st, 2021
  • Colin Bristow of "UBS" Initiated at Strong Buy and Held Target at $99 on, Monday, February 1st, 2021

Publication Contributing Sources